Development of a novel Hsp70-based DNA vaccine as a multifunctional antigen delivery system

The preparation of leukemia cell vaccine expressing BCG heat shock protein 70 and anti-leukemia effect in vitro

“…Moreover, HSP70 itself has a strong immunogenicity and can be an adjuvant, without the need for additional adjuvant. Furthermore, HSP used in whole-cell vaccine has a unique advantage, that is, without identification and separation of tumor antigen, from the impact of tumor antigenic modulation, and breaking the tumor tolerance and avoiding the problem of tumor immune escape [29][30][31]. In this study, the recombinant eukaryotic expression vector pDisplay-HSP70 was successfully constructed, with signal peptide and PDGFR transmembrane sequence lying at the two flanks of the multiple cloning sites, and expressed on the cell surface.…”

Endotoxin-minimized HIV-1 p24 fused to murine hsp70 activates dendritic cells, facilitates endocytosis and p24-specific Th1 response in mice

“…It was reported that either hsp70 or gp96 could activate DC, mostly through various cell surface receptors such as CD36, CD11b, SR-A, SREC-1, and still discussed TLR-2, TLR-4, or [11][12][13][14][15][16][17][18]. These properties make hsp70 and gp96 promising and commonly used carriers for vaccine antigens aiming at eliciting cell-mediated antigen-specific immune responses [16,[18][19][20][21].…”

Comparison of antigen expression from plasmid DNA in tumor-free and antigen-expressing tumor-bearing mice

“…Seven days after the last immunization, serum samples were collected from the tail vein of mice to measure anti-OVA IgG antibodies by an enzymelinked immunosorbent assay (ELISA) as described previously. 3,4 In brief, 96-well flat-bottom polystyrene plate was coated with OVA (1 mg/ml) by overnight incubation at 4°C. The wells were blocked with 5% BSA-containing phosphate buffered saline with Tween-20 (0.5 w/w% Tween-20 in PBS).…”

“…Seven days after the last immunization, spleens were isolated from the immunized mice and cytotoxic T lymphocyte (CTL) assay was performed as described previously. 3,4 In brief, spleen cells were restimulated with mitomycin C-treated EG7-OVA for 5 d in vitro. Target cells, EG7-OVA, were labeled with 51 Cr by incubating with Na 2 51 CrO 4 (Daiichi Radioisotope Labs, Tokyo, Japan).…”

“…2 Immunization of naïve mice with DNA vaccines generally induces antigen-specific immune responses, which is strong enough to reject tumor challenge. 3,4 However, high prophylactic effects of DNA vaccines do not guarantee their therapeutic effects in established cancer.…”